Jeff Kopacz

Jeff has extensive intellectual property experience, including experience with building and defending intellectual property protection for platform-based technologies and FDA-approved biotherapeutics. Prior to joining SalioGen Therapeutics, he served as Vice-President of Intellectual Property at Omega Therapeutics, where he led intellectual property and contract activities related to their genomic control technology.

Prior to joining Omega, Jeff was at Alnylam Pharmaceuticals, Inc., for 10 years and served most recently as Senior Director, Senior Intellectual Property counsel. His primary responsibilities included developing and executing the intellectual property strategy for Alnylam’s therapeutic candidates, and he helped build the intellectual property portfolio for the world’s first RNAi-approved medicines, Onpattro, Givlaari, Oxlumo, and Leqvio. He also helped defend the Alnylam platform intellectual property estate from patent challenges and worked closely with business development supporting various license agreements and collaborations.

Prior to joining Alnylam, Jeff was an attorney at Edwards Angell Palmer & Dodge LLP (now Locke Lord LLP), where he built the intellectual property estates for numerous commercial products and counseled clients on intellectual property matters in the biotechnology and pharmaceutical industries. Jeff began his biopharmaceutical career at Millennium Pharmaceuticals, now Takeda Pharmaceuticals.

Jeff received his undergraduate degree in microbiology from the University of Massachusetts at Amherst, his graduate degree in molecular microbiology and immunology from Johns Hopkins University, and a law degree from Suffolk University Law School.